Wegovy Pill Arrives in UK as US Employers Plan to Drop GLP-1 Coverage in 2027

LONDON

By Emma Smith

Novo Nordisk's Wegovy launches in oral pill form in the UK while a Reuters survey finds some US employers planning to drop GLP-1 obesity drug coverage by 2027.

Novo Nordisk's Wegovy will be available in oral pill form in the United Kingdom for the first time, the BBC reported Wednesday, marking the most significant product development to date for the company's flagship weight-loss franchise. The pill arrives as Reuters reported that some U.S. employers are planning to drop coverage of GLP-1 obesity drugs by 2027, citing rapidly rising prescription volumes and the consequent strain on health-plan budgets.

Together, the two developments capture the contradictory pressures shaping the GLP-1 obesity drug market: explosive consumer demand and growing access via new formulations on one hand, and a tightening of payer coverage that could substantially restrict who can afford the drugs on the other.

The BBC story focused on the UK launch. The British National Health Service confirmed that Wegovy in pill form will be available to UK patients beginning later this year through both NHS and private channels, with NHS prescribing limited to specific patient categories under existing weight-management treatment protocols. The Guardian, in a separate report, framed the launch as Wegovy pills "to be available for patients in UK to buy" — suggesting that private cash-pay availability will run alongside any NHS coverage.

The pill formulation is significant because it lowers the practical barrier to use compared with the injectable form. Studies have shown that many patients are deterred from injectable weight-loss therapies by needle aversion, even when the therapies are otherwise well-tolerated and effective. Whether the oral version produces clinically meaningful weight loss in U.K. patients at scale will be one of the year's most-watched real-world drug-evaluation questions.

On the U.S. side, the Reuters report Wednesday found that a meaningful number of U.S. employers are planning to drop GLP-1 obesity drug coverage from their health plans by 2027. The publication cited a survey of large employer benefit managers and consultants who said the increasing share of employees who are filling GLP-1 prescriptions had pushed plan costs to levels that several employers viewed as unsustainable.

The Reuters reporting did not specify which named employers are dropping coverage, but the trade-publication conventional wisdom has been that the calculations driving the shift cut across industries. Several large national employers have already added preauthorization requirements, body-mass-index thresholds and prescribing-physician limits to their GLP-1 coverage. The 2027 timeline cited in the Reuters survey suggests that more dramatic restrictions — including outright exclusions — may follow in the next 18 months.

The patient implications of the employer pullback are stark. The list price of Wegovy in the U.S. is roughly $1,350 per month; without insurance coverage, the cost would put the medication out of reach for the vast majority of patients who could benefit from it. Both Novo Nordisk and Eli Lilly have established direct-to-consumer cash-pay programs that lower the effective price meaningfully, but those programs remain expensive for most household budgets.

BioPharma Dive reported separately Wednesday that AstraZeneca is making what the publication described as an "extensive" push into the obesity drug market, with the company committing significant research-and-development resources to a portfolio of next-generation weight-management compounds. The AstraZeneca push is a notable structural development because it expands the field of major pharmaceutical competitors from the current Eli Lilly and Novo Nordisk duopoly into a broader contest involving several firms.

Yahoo Finance, in a piece headlined "Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy," characterized the competition between the two existing leaders as having entered a new phase, with both companies racing to establish durable positions in oral formulations, next-generation injectables, and combination therapies aimed at multiple conditions including type 2 diabetes, cardiovascular risk and renal disease.

The competitive dynamics matter for patients because they tend, over time, to drive down per-unit prices and improve access. The current GLP-1 pricing environment, however, has so far been notable for the absence of meaningful price competition between the two existing leaders, despite both companies producing therapies that compete in similar patient populations.

Whether AstraZeneca's market entry, alongside potential cardiovascular and combination indications from Eli Lilly's retatrutide pipeline and Novo Nordisk's CagriSema combination, will produce the kind of competitive price pressure that has historically characterized maturing drug markets remains to be seen.

For now, the central tension facing U.S. patients is between rapidly expanding availability of new formulations — including the pill form arriving in the UK and presumably soon in the U.S. — and a tightening of insurance coverage that could put even existing therapies out of reach for many.

The FDA has not yet approved the pill form of Wegovy in the United States. Novo Nordisk has previously indicated that a U.S. regulatory submission is in preparation, but no specific timeline has been publicly disclosed.

The 2027 employer-coverage decisions are not yet final. Several human-resources consultancies surveyed by Reuters noted that the picture could shift if Novo Nordisk or Eli Lilly offered meaningful rebates or net-price reductions to ease the budgetary strain. Neither company has publicly committed to such concessions.